Indivior Pharmaceuticals ... (INDV)
Indivior Pharmaceuticals Inc. (INDV) Stock Price, Analysis & Data
| Bid | 27.95 |
| Market Cap | 4.6B |
| Revenue (ttm) | 1.33B |
| Net Income (ttm) | 356M |
| Beta | 1.14 |
| EPS (ttm) | 2.79 |
| PE Ratio (ttm) | 13.98 |
| Forward PE | 7.99 |
| P/B (ttm) | -22.13 |
| P/S (ttm) | 3.46 |
| Earnings Date | Nov 5, 2026 |
| Ask | 48.92 |
| Volume | 925,962 |
| Avg. Volume (20D) | 2,001,696 |
| Open | 38.00 |
| Previous Close | 38.22 |
| Day's Range | 37.82 - 39.14 |
| 52-Week Range | 22.22 - 42.81 |
| Analyst | Strong Buy |
| Price Target | 50 (28.17%) |
| Dividends | n/a |
| Ex-Dividend Date | Jun 16, 2016 |
About INDV
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; a...
Financial Performance
In 2025, Indivior Pharmaceuticals's revenue was 1.24B, an increase of 4.29% compared to the previous year's 1.19B. Earnings were 210M, an increase of 2,900%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for INDV stock is "Strong Buy". The 12-month stock price forecast is 50, which is upside of 28.17% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
